Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2024-08-01 Board/Management Inform…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Życiorys - Paweł Mańdok
Board/Management Information Classification · 89% confidence The document provided is a detailed curriculum vitae (CV) or professional profile for an individual named Paweł Mańdok. It lists professional experience, responsibilities, education, and additional information. This type of document is not a standard regulatory financial filing (like 10-K, ER, or IR) nor is it a specific corporate announcement (like DIV, MANG, or DIRS). It appears to be background material, possibly related to a board appointment, management change, or a general investor/stakeholder information document that doesn't fit the defined categories. Since it details management experience and structure, it is closest in theme to Board/Management Information (MANG) or Governance Information (CGR), but it is fundamentally a resume. Given the strict definitions, and lacking any explicit announcement context, the most appropriate fallback category for non-standard corporate/personnel documentation that isn't a formal filing is 'Regulatory Filings' (RNS), as it is a miscellaneous document type not covered elsewhere. However, if this document were submitted in the context of a management change, MANG would be relevant. Since it is a standalone CV, RNS is the safest fallback, though I will lean towards MANG as it heavily details senior management roles.
2024-08-01 Polish
Życiorys - Hubert Staszewski
Board/Management Information Classification · 98% confidence The document is titled "Hubert Staszewski - Życiorys kandydata na członka Rady Nadzorczej" which translates to "Hubert Staszewski - Biography of a candidate for the Supervisory Board member". This document details the professional background, education, and previous board memberships of an individual being proposed for a position on the company's governing body (Supervisory Board). This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management, as this is the supporting material for such a change (a candidate's CV).
2024-08-01 Polish
Zgłoszenie kandydatów na Członka Rady Nadzorczej PolTREG S.A. - Content (PL)
Board/Management Information Classification · 95% confidence The document text, written in Polish, discusses the receipt of nominations for candidates (Hubert Staszewski and Paweł Mańdok) for the Supervisory Board (Rada Nadzorcza) of the company (PolTREG S.A.) ahead of an Extraordinary General Meeting (Nadzyczajne Walne Zgromadzenie). It explicitly mentions that the professional resumes ('Życiorysy zawodowe') of the candidates are attached as appendices to the report. This content directly relates to the composition of the board of directors/supervisory board and the process leading up to a shareholder meeting where such appointments are confirmed. This aligns best with the 'Board/Management Information' (MANG) category, which covers announcements of changes in the board of directors or senior management. Although it relates to an upcoming AGM, the core subject is the nomination of board members, not the AGM materials themselves (AGM-R) or proxy solicitation (PSI).
2024-08-01 Polish
Warunkowa autoryzacja Europejskiej Agencji Leków badania klinicznego fazy II w projekcie PreTreg (cukrzyca przedobjawowa typu 1) - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is very short (616 characters) and announces that the Management Board of PolTREG S.A. received conditional authorization from the European Medicines Agency (EMA) for a Phase II clinical trial (PreTreg project for pre-symptomatic Type 1 diabetes). It explicitly states that the final decision will follow the fulfillment of certain conditions and that the Issuer will inform about the final decision in a separate current report (raport bieżący ESPI). Because this is a specific announcement regarding regulatory/clinical trial progress, and it is not a full report (like AR or IR), it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update that doesn't match the other specialized codes (like LTR for legal proceedings or CAP for financing). Given the nature of the announcement (regulatory/clinical trial update), RNS is the most appropriate fallback.
2024-07-23 Polish
Zaktualizowane ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia
AGM Information Classification · 98% confidence The document is titled "OGŁOSZENIE O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA" (Announcement on Convening an Extraordinary General Meeting) and details the date, time, location, and agenda for a shareholder meeting on August 8, 2024. It extensively covers procedures for participation, voting rights, proxy appointments, and the record date ('Dzień Rejestracji'). This content is characteristic of materials related to convening a general meeting, which falls under the scope of AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since the primary focus is the formal convening notice and the rules governing the meeting itself, AGM-R is the most precise fit, as it covers 'Presentations and materials shared during the Annual General Meeting (AGM)'—and by extension, the notice to convene it. It is not a DEF 14A (Remuneration) or a DVA (Voting Results). Given the explicit mention of convening the meeting, AGM-R is selected.
2024-07-19 Polish
Zmiana miejsca odbycia Nadzwyczajnego Walnego Zgromadzenia Akcjonariuszy PolTREG S.A. - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a formal announcement from the Management Board (Zarząd) of PolTREG S.A. regarding a change in the venue for the Extraordinary General Meeting of Shareholders (Nadzwyczajne Walne Zgromadzenie Akcjonariuszy) scheduled for August 8, 2024. This is a specific notification related to the logistics of a shareholder meeting, referencing a prior announcement. Since it is an announcement about the logistics of a meeting rather than the meeting materials themselves (AGM-R) or the voting results (DVA), it falls under general regulatory announcements. Given the specific nature of announcing meeting logistics changes, and the lack of a more precise category for meeting logistics updates, it is best classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure to the market about an upcoming corporate event.
2024-07-19 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.